Target Price | $130.56 |
Price | $112.69 |
Potential | 15.86% |
Number of Estimates | 29 |
29 Analysts have issued a price target Gilead Sciences 2026 . The average Gilead Sciences target price is $130.56. This is 15.86% higher than the current stock price. The highest price target is $150.15 33.24% , the lowest is $98.98 12.17% . | |
A rating was issued by 36 analysts: 28 Analysts recommend Gilead Sciences to buy, 8 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2026 of 15.86% . Most analysts recommend the Gilead Sciences stock at Purchase. |
30 Analysts have issued a sales forecast Gilead Sciences 2025 . The average Gilead Sciences sales estimate is $29.3b . This is 1.68% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $30.7b 6.26% , the lowest is $27.9b 3.21% .
This results in the following potential growth metrics:
2024 | $28.8b | 6.04% |
---|---|---|
2025 | $29.3b | 2.07% |
2026 | $30.5b | 3.95% |
2027 | $32.2b | 5.63% |
2028 | $33.6b | 4.36% |
2029 | $35.2b | 4.78% |
2030 | $36.9b | 4.66% |
2031 | $37.5b | 1.62% |
2032 | $37.2b | 0.81% |
16 Analysts have issued an Gilead Sciences EBITDA forecast 2025. The average Gilead Sciences EBITDA estimate is $14.8b . This is 2.44% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $16.8b 10.71% , the lowest is $13.3b 12.42% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $13.6b | 8.28% |
---|---|---|
2025 | $14.8b | 8.78% |
2026 | $15.6b | 5.57% |
2027 | $16.6b | 6.03% |
2028 | $19.2b | 16.08% |
2029 | $20.1b | 4.84% |
2030 | $20.2b | 0.22% |
2031 | $20.3b | 0.76% |
2032 | $21.8b | 6.98% |
2024 | 47.28% | 2.12% |
---|---|---|
2025 | 50.39% | 6.58% |
2026 | 51.17% | 1.55% |
2027 | 51.37% | 0.39% |
2028 | 57.13% | 11.21% |
2029 | 57.17% | 0.07% |
2030 | 54.75% | 4.23% |
2031 | 54.29% | 0.84% |
2032 | 58.55% | 7.85% |
30 Gilead Sciences Analysts have issued a net profit forecast 2025. The average Gilead Sciences net profit estimate is $10.3b . This is 62.59% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $10.9b 72.54% , the lowest is $9.7b 54.29% .
This results in the following potential growth metrics and future Net Margins:
2024 | $480m | 91.53% |
---|---|---|
2025 | $10.3b | 2,037.78% |
2026 | $10.9b | 6.07% |
2027 | $11.8b | 8.64% |
2028 | $12.6b | 6.15% |
2029 | $13.8b | 9.74% |
2030 | $14.8b | 7.28% |
2031 | $15.2b | 2.56% |
2032 | $15.3b | 1.01% |
2024 | 1.67% | 92.01% |
---|---|---|
2025 | 34.96% | 1,994.25% |
2026 | 35.67% | 2.03% |
2027 | 36.69% | 2.86% |
2028 | 37.32% | 1.72% |
2029 | 39.09% | 4.74% |
2030 | 40.07% | 2.51% |
2031 | 40.44% | 0.92% |
2032 | 41.18% | 1.83% |
30 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences EPS is $8.26 . This is 64.54% higher than earnings per share in the financial year 2024. The highest EPS forecast is $8.77 74.70% , the lowest is $7.84 56.18% .
This results in the following potential growth metrics and future valuations:
2024 | $0.38 | 91.56% |
---|---|---|
2025 | $8.26 | 2,073.68% |
2026 | $8.76 | 6.05% |
2027 | $9.52 | 8.68% |
2028 | $10.11 | 6.20% |
2029 | $11.09 | 9.69% |
2030 | $11.90 | 7.30% |
2031 | $12.20 | 2.52% |
2032 | $12.33 | 1.07% |
Current | 22.45 | 77.45% |
---|---|---|
2025 | 13.64 | 39.24% |
2026 | 12.86 | 5.72% |
2027 | 11.84 | 7.93% |
2028 | 11.15 | 5.83% |
2029 | 10.16 | 8.88% |
2030 | 9.47 | 6.79% |
2031 | 9.23 | 2.53% |
2032 | 9.14 | 0.98% |
Based on analysts' sales estimates for 2025, the Gilead Sciences stock is valued at an EV/Sales of 5.44 and an P/S ratio of 4.76 .
This results in the following potential growth metrics and future valuations:
Current | 5.53 | 23.44% |
---|---|---|
2025 | 5.44 | 1.69% |
2026 | 5.23 | 3.80% |
2027 | 4.95 | 5.33% |
2028 | 4.74 | 4.18% |
2029 | 4.53 | 4.56% |
2030 | 4.33 | 4.45% |
2031 | 4.26 | 1.59% |
2032 | 4.29 | 0.82% |
Current | 4.84 | 29.40% |
---|---|---|
2025 | 4.76 | 1.66% |
2026 | 4.58 | 3.80% |
2027 | 4.34 | 5.33% |
2028 | 4.16 | 4.18% |
2029 | 3.97 | 4.56% |
2030 | 3.79 | 4.45% |
2031 | 3.73 | 1.59% |
2032 | 3.76 | 0.82% |
Gilead Sciences...
Analyst | Rating | Action | Date |
---|---|---|---|
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Sep 16 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 08 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Aug 08 2025 |
Truist Securities |
Hold
➜
Buy
|
Upgrade | Aug 08 2025 |
Needham |
Hold
➜
Buy
|
Upgrade | Jul 25 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | May 21 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Apr 25 2025 |
Analyst Rating | Date |
---|---|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Sep 16 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 08 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Aug 08 2025 |
Upgrade
Truist Securities:
Hold
➜
Buy
|
Aug 08 2025 |
Upgrade
Needham:
Hold
➜
Buy
|
Jul 25 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
May 21 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Apr 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.